Bioventix (BVXP) H2 2025 earnings summary

Executive summary

• Revenue for the year ended 30 June 2025 decreased by 3.6% to £13.1m, with profit before tax down 4.8% to £10.1m year-over-year.

• Cash balances at year-end were £5.1m, down from £6.0m the previous year.

• The core business faced headwinds, particularly in China, but neurology diagnostics showed significant progress.

• Dividend payments totaled 150p per share for the year, with an 80p final dividend declared post year-end.

Financial highlights

• Turnover: £13.1m (2024: £13.6m), down 3.6% year-over-year.

• Profit before tax: £10.1m (2024: £10.6m), down 4.8%.

• Net profit: £7.6m (2024: £8.1m).

• Cash at bank: £5.1m (2024: £6.0m).

• EPS: 145.27p basic, 143.29p diluted (2024: 155.12p, 152.86p).

• Dividend paid: 157p per share (2024: 158p).

Outlook and guidance

• Modest revenue decline expected in 2025/26 due to continued headwinds in the core business.

• Growth anticipated from neurology diagnostics and expanded troponin testing applications.

• Ongoing investment in research and development, especially in neurology and environmental diagnostics.